Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: A case report and review of the literature

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 6, 2013, Pages 526-527

  Dell'Orto, V G ^a   Bianchetti, M G ^a   Brazzola, P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

adverse effects; deferasirox; metabolic acidosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CARBON DIOXIDE; CHLORIDE; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; GLUCOSE; HEMOGLOBIN; PHOSPHATE; POTASSIUM; SODIUM; TRIACYLGLYCEROL LIPASE; UREA; URIC ACID;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOACIDURIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BICARBONATE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PH; BLOOD TRANSFUSION; CALCIUM BLOOD LEVEL; CARBON DIOXIDE TENSION; CASE REPORT; CHLORIDE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOURICEMIA; KIDNEY FAILURE; LEUKOCYTE COUNT; METABOLIC ACIDOSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NARANJO ADVERSE DRUG REACTION SCALE; NAUSEA AND VOMITING; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; REVIEW; SODIUM BLOOD LEVEL; THROMBOCYTE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADVERSE EFFECTS; DEFERASIROX; METABOLIC ACIDOSIS;

ACIDOSIS; ACIDOSIS, RENAL TUBULAR; ADOLESCENT; BENZOATES; BETA-THALASSEMIA; CHLORINE; FEMALE; HUMANS; IRON CHELATING AGENTS; TRIAZOLES;

EID: 84886952999     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12095     Document Type: Review

References (12)

1. Cappellini MD, Pattoneri P,. Oral iron chelators. Annu Rev Med, 2009; 60: 25-38.
2. Vichinsky E,. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Pediatrics, 2008; 121: 1253-1256.
3. Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.
4. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A,. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother, 2010; 44: 219-221.
5. Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M,. Fanconi syndrome due to deferasirox. Am J Kidney Dis, 2009; 54: 931-934.
6. Rheault MN, Bechtel H, Neglia JP, Kashtan CE,. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer, 2011; 56: 674-676.
7. Wei HY, Yang CP, Cheng CH, Lo FS,. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion, 2011; 51: 949-954.
8. Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H,. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol, 2010; 32: 564-567.
9. Even-Or E, Becker-Cohen R, Miskin H,. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol, 2010; 85: 132-134.
10. Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M,. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant, 2010; 25: 2376-2378.
11. Rodríguez-Soriano J, Vallo A,. Renal tubular acidosis. Pediatr Nephrol, 1990; 4: 268-275.
12. Baum M,. Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire. J Pediatr Hematol Oncol, 2010; 32: 525-526.